首页> 外文期刊>Case Reports in Gastroenterology >Palliative Endoscopic Ultrasound Biliary Drainage for Advanced Malignant Biliary Obstruction: Should It Replace the Percutaneous Approach?
【24h】

Palliative Endoscopic Ultrasound Biliary Drainage for Advanced Malignant Biliary Obstruction: Should It Replace the Percutaneous Approach?

机译:晚期恶性胆道梗阻的姑息性内镜超声胆道引流术:是否应取代经皮入路?

获取原文
           

摘要

Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD) are the standard of care in malignant biliary obstruction cases. Recently, endoscopic ultrasound-guided biliary drainage (EUS-BD) has been widely used after unsuccessful ERCP. However, the patient’s clinical impact of EUS-BD over PTBD is still not obvious. Therefore, this case series study aims to evaluate the clinical outcomes of patients with advanced malignant biliary obstruction who underwent EUS-BD after failed ERCP. A retrospective database study was performed between January 2016 and June 2018 in patients with advanced malignant biliary obstruction. Patients were consecutively enrolled without randomization. Treatment options consisted of ERCP and PTBD or EUS-BD if ERCP failed. Based on 144 biliary obstruction cases, 38 patients were enrolled; 24 (63.2%) were men. The patients’ mean age was 66.8 ± 12.36 years. The most common cause of malignant biliary obstruction was pancreatic cancer (44.7%). Biliary drainage was achieved by ERCP (39.5%), PTBD (39.5%), and EUS-BD (21.1%). The technical success rate was 86.7% by PTBD and 87.5% by EUS-BD (p = 1.000), while the clinical success rate was 93.3% by PTBD and 62.5% by EUS-BD (p = 0.500). The median survival in patients who underwent PTBD versus those wo underwent EUS-BD was 11 versus 3 months (log-rank p = 0.455). In conclusion, there is no significant advantage of EUS-BD when compared to PTBD in terms of clinical success and survival benefit in advanced malignant biliary obstruction.
机译:内镜逆行胰胆管造影(ERCP)和经皮经肝胆道引流(PTBD)是恶性胆道梗阻病例的治疗标准。最近,内镜超声引导胆汁引流术(EUS-BD)在ERCP失败后得到了广泛的应用。但是,EUS-BD优于PTBD对患者的临床影响仍然不明显。因此,本病例研究旨在评估ERCP失败后行EUS-BD的晚期恶性胆道梗阻患者的临床结局。在2016年1月至2018年6月之间对晚期恶性胆道梗阻患者进行了回顾性数据库研究。患者连续入组,无随机分组。如果ERCP失败,则治疗方案包括ERCP和PTBD或EUS-BD。基于144例胆道梗阻病例,其中38例入选。 24名(63.2%)是男性。患者的平均年龄为66.8±12.36岁。胆道恶性阻塞最常见的原因是胰腺癌(44.7%)。 ERCP(39.5%),PTBD(39.5%)和EUS-BD(21.1%)实现了胆道引流。 PTBD的技术成功率为86.7%,EUS-BD的技术成功率为87.5%(p = 1.000),而PTBD的临床成功率为93.3%,EUS-BD的临床成功率为62.5%(p = 0.500)。接受PTBD的患者与接受EUS-BD的患者的中位生存期分别为11个月和3个月(对数秩p = 0.455)。总之,就晚期恶性胆道梗阻的临床成功率和生存获益而言,与PTBD相比,EUS-BD没有显着优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号